Conference Reports

By Jenny Powers

PARIS -- September 18, 2018 -- Adding methotrexate to adalimumab increased the response in patients with psoriasis who demonstrated a previous suboptimal response to adalimumab monotherapy, according to results of a single-arm, open-label, longitudinal study of 46 patients...

By Jenny Powers

PARIS -- September 18, 2018 -- Tildrakizumab provided significant improvements to the Dermatology Life Quality Index (DLQI) that were sustained up to 64 weeks in patients with moderate-to-severe psoriasis, according to results from a post hoc pooled analysis of data from...

By Jenny Powers

PARIS -- September 18, 2018 -- Tildrakizumab is highly effective in patients with moderate to severe plaque psoriasis regardless of whether they had received prior biologic therapy, according to findings from a post hoc pooled analysis of data from the reSURFACE-1 and...

By Jenny Powers

PARIS -- September 18, 2018 -- Patients with moderate to severe psoriasis treated with risankizumab for 16 weeks showed superior responses that remained consistent across baseline demographics and disease characteristics, according to findings from a pooled, retrospective...

By Jenny Powers

PARIS -- September 17, 2018 -- Patients with plaque psoriasis who failed to respond to initial treatment with etanercept appear to show response to certolizumab pegol, researchers reported here at the 27th Congress of the European Academy of Dermatology and Venereology (...

By Michael Bassett

SAN DIEGO -- February 22, 2018 -- A proposed biosimilar of adalimumab, MSB11022, shows equivalent efficacy, immunogenicity, and safety to adalimumab in patients with moderate to severe psoriasis, according to a study presented here at the 2018 Annual Meeting of the...

By Michael Bassett

SAN DIEGO -- February 21, 2018 -- Treatment with ixekizumab for 12 weeks significantly reduces the impact of genital psoriasis on sexual activity and improves quality of life, according to a study presented here at the 2018 Annual Meeting of the American Academy of...

By Michael Bassett

SAN DIEGO -- February 20, 2018 -- Mirikizumab is effective in treating patients with moderate to severe plaque psoriasis and significantly improves their quality of life, according to a study presented here at the 2018 Annual Meeting of the American Academy of...

By Michael Bassett

SAN DIEGO -- February 20, 2018 -- The use of ixekizumab (IXE) to treat patients with genital psoriasis can provide them with rapid and significantly greater improvement in the severity of symptoms, according to a study presented here at the 2018 Annual Meeting of the...

By Jill Stein

SAN DIEGO -- November 8, 2017 -- Investigators have found no evidence of an increased risk of venous thromboembolic events (VTE) in patients treated with tofacitinib for rheumatoid arthritis (RA), psoriasis (PsO), psoriatic arthritis (PsA), or ulcerative colitis (UC).

...

Pages